|
Market Cap (16-May) $2,292,313,856 (333rd) |
Close (30-Jun) $1.14 |
Volume (30-Jun) 2,606,681 |
Shortsold (5-May) 72,824,861 (5.70%) (40th) |
|
52w High $3.37 |
52w Low $0.88 |
P/E 454.55 |
EPS -0.14 |
MSB released this announcement to the ASX on 9 February 2023, 9:39. The announcement is not marked as price sensitive, and is 3 page(s) in length and 187.83kb in size.
You can view all announcements from MSB and see how they appear on a price chart on the announcements page.
At the date of this announcement, MSB was 3.976% short sold according to ASIC data. It was ranked the 48th most shorted stock on the ASX. It is now ranked as the 40th most shorted stock on the ASX with 5.699% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from MSB | |
|---|---|
| Change of Director's Interest Notice | 13 June 2023, 8:56 |
| Mesoblast Director Appointed to Strategic Advisory Role | 5 June 2023, 9:41 |
| MSB Reports Q3 Financial Results and Operational Highlights | 26 May 2023, 8:32 |
| FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP | 9 February 2023, 9:39 |
| Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD | 1 February 2023, 9:30 |
| Quarterly Activities/Appendix 4C Cash Flow Report | 31 January 2023, 18:22 |
| Appendix 3G, Appendix 3H and Appendix 3Ys | 16 January 2023, 18:36 |
You must be logged in to post a reply.
Mesoblast 